Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report

[1]  R. Dinsmore,et al.  The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention , 1993, Cardiovascular Drugs and Therapy.

[2]  Abu T. M. Serajuddin,et al.  Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (ACE) Inhibitors , 1992, Pharmaceutical Research.

[3]  E. Lonn,et al.  The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. , 2001, The American journal of cardiology.

[4]  F. Lallemand,et al.  Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin. , 2000, Circulation.

[5]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[6]  H. Haber,et al.  Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) , 2000, Journal of the American College of Cardiology.

[7]  D. Koehl,et al.  Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog , 1999, Basic Research in Cardiology.

[8]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction , 1999, The Lancet.

[9]  U. Ikeda,et al.  Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. , 1999, The American journal of cardiology.

[10]  A. Zeiher,et al.  Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options , 1999, Journal of internal medicine.

[11]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[12]  H. Drexler,et al.  Endothelial dysfunction in human disease. , 1999, Journal of molecular and cellular cardiology.

[13]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. , 1999, Lancet.

[14]  R. Dinsmore,et al.  Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. , 1999, The American journal of cardiology.

[15]  I. Nishio,et al.  [Angiotensin I converting enzyme]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[16]  H. Drexler,et al.  Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.

[17]  D. Vaughan,et al.  Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. , 1998, Hypertension.

[18]  R. Schrier,et al.  Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. , 1998, The American journal of cardiology.

[19]  J. Morrow,et al.  Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. , 1998, The New England journal of medicine.

[20]  R. Virmani,et al.  Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. , 1998, The Journal of clinical investigation.

[21]  I Maruyama,et al.  Biology of endothelium , 1998, Lupus.

[22]  J. Ménard,et al.  Local angiotensin II generation in the rat heart: role of renin uptake. , 1998, Circulation research.

[23]  K. Bernstein.  The role of tissue angiotensin-converting enzyme (ACE): studies of ACE mutant mice. , 1998, The American journal of cardiology.

[24]  H. Crijns,et al.  Functional effects of ACE-inhibitors on angiotensin I conversion in human vasculature , 1998 .

[25]  P. Anversa,et al.  Apoptosis and myocardial infarction , 1998, Basic Research in Cardiology.

[26]  G. Berkenboom,et al.  Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism. , 1997, Hypertension.

[27]  M. Ruzicka,et al.  ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy. , 1997, The American journal of physiology.

[28]  M. Pfeffer,et al.  Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. , 1997, Circulation.

[29]  J. Zhuo,et al.  Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. , 1997, Circulation.

[30]  K. Weber,et al.  Cultured myofibroblasts generate angiotensin peptides de novo. , 1997, Journal of molecular and cellular cardiology.

[31]  P. Kovanen,et al.  Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. , 1997, Circulation.

[32]  H. Drexler,et al.  Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. , 1997, Circulation.

[33]  C. Bauters,et al.  ACE inhibition accelerates endothelial regrowth in vivo: a possible explanation for the benefit observed with ACE inhibitors following arterial injury. , 1997, Biochemical and biophysical research communications.

[34]  T. Coffman,et al.  Angiotensin‐II receptors: new targets for antihypertensive therapy , 1997, Clinical cardiology.

[35]  A. Danser,et al.  Is there an internal cardiac renin-angiotensin system? , 1996, Heart.

[36]  E. Miyamoto,et al.  Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. , 1996, Circulation.

[37]  K. Lindpaintner,et al.  Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[39]  G. B. John Mancini,et al.  Angiotensin Converting Enzyme Inhibition, with Quinapril, Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: the TREND Study (Trial on REversing ENdothelial Dysfunction) , 1996 .

[40]  T. Lüscher,et al.  Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. , 1996, Circulation.

[41]  M. Ruzicka,et al.  Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. , 1995, Circulation.

[42]  F. Pieruzzi,et al.  Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. , 1995, Circulation.

[43]  L. Ruilope,et al.  Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. , 1995, Nephron.

[44]  T. Maniatis,et al.  Transcriptional regulation of endothelial cell adhesion molecules : NF-icB and cytokine-inducible enhancers , 2004 .

[45]  D. Zeeuw,et al.  Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  D. Vaughan,et al.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. , 1995, The Journal of clinical investigation.

[47]  B. Berk,et al.  Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. , 1995, Hypertension.

[48]  H. Schunkert,et al.  Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. , 1995, Hypertension.

[49]  R. Bohle,et al.  Cellular distribution of angiotensin-converting enzyme after myocardial infarction. , 1995, Hypertension.

[50]  M. Ruzicka,et al.  Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. , 1995, Circulation.

[51]  O. Hess,et al.  Intracardiac Angiotensin‐Converting Enzyme Inhibition Improves Diastolic Function in Patients With Left Ventricular Hypertrophy due to Aortic Stenosis , 1994, Circulation.

[52]  B. Swynghedauw,et al.  Activation of Angiotensinogen and Angiotensin‐Converting Enzyme Gene Expression in the Left Ventricle of Senescent Rats , 1994, Circulation.

[53]  H. Schunkert,et al.  Angiotensin‐Converting Enzyme Inhibition Prolongs Survival and Modifies the Transition to Heart Failure in Rats With Pressure Overload Hypertrophy Due to Ascending Aortic Stenosis , 1994, Circulation.

[54]  C. Johnston,et al.  Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. , 1994, European journal of pharmacology.

[55]  T. Unger,et al.  Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. , 1994, Cardiovascular research.

[56]  C. Johnston.  Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. , 1994, Hypertension.

[57]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[58]  J. Sadoshima,et al.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro , 1993, Cell.

[59]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[60]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[61]  Therapy Study Investigators.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.

[62]  R. Alexander,et al.  Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. , 1993, The Journal of clinical investigation.

[63]  C. Johnston,et al.  The cardiac renin-angiotensin system in heart failure. , 1993, American heart journal.

[64]  G. Hasenfuss,et al.  Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions. , 1993, Circulation.

[65]  H. Urata,et al.  Measurement of angiotensin I converting enzyme inhibition in the heart. , 1993, Circulation research.

[66]  H. Schunkert,et al.  Distribution and Functional Significance of Cardiac Angiotensin Converting Enzyme in Hypertrophied Rat Hearts , 1993, Circulation.

[67]  B. Kasiske,et al.  Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis , 1993, Annals of Internal Medicine.

[68]  S. Chaki,et al.  Cloning, expression and regulation of angiotensin II receptors. , 1994, Journal of hypertension.

[69]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[70]  D. Nash.  Comparative properties of angiotensin-converting enzyme inhibitors: relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications. , 1992, The American journal of cardiology.

[71]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[72]  H. Schunkert,et al.  Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. , 1991, Circulation research.

[73]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[74]  P. Timmermans,et al.  Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. , 1991, Hypertension.

[75]  C. Johnston,et al.  Localization of angiotensin converting enzyme in rat heart. , 1991, Circulation research.

[76]  K. Misono,et al.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.

[77]  H. Schunkert,et al.  Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. , 1990, The Journal of clinical investigation.

[78]  K. Baker,et al.  Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. , 1990, The American journal of physiology.

[79]  C. Johnston,et al.  Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats , 1990, British journal of pharmacology.

[80]  C. Johnston,et al.  INCREASED CARDIAC ANGIOTENSIN‐CONVERTING ENZYME IN RATS WITH CHRONIC HEART FAILURE , 1990, Clinical and experimental pharmacology & physiology.

[81]  B. Healy,et al.  Angiotensin II-forming pathways in normal and failing human hearts. , 1990, Circulation research.

[82]  Bin Chen,et al.  Inhibition of Angiotensin‐Converting Enzyme (ACE) in Plasma and Tissue , 1990, Journal of cardiovascular pharmacology.

[83]  M. Peach,et al.  The angiotensin II receptor and the actions of angiotensin II. , 1990, Journal of cardiovascular pharmacology.

[84]  C. Johnston,et al.  Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. , 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[85]  L. Ruilope,et al.  Control of hypertension with the angiotensin converting enzyme inhibitor captopril reduces glomerular proteinuria , 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[86]  G. Riegger,et al.  Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. , 1988, The American journal of cardiology.

[87]  Skidgel Ra,et al.  The angiotensin I-converting enzyme. , 1977 .

[88]  H. Cheung,et al.  Concentrations of angiotensin-converting enzyme in tissues of the rat. , 1971, Biochimica et biophysica acta.

[89]  J. Vane,et al.  Fate of Angiotensin I in the Circulation , 1968, Nature.

[90]  J. Tomaszewski,et al.  Renin and angiotensin. , 1968, Lancet.